SHYNDEC(SH:600420) Xin Lang Cai Jing·2025-09-12 08:46Core Viewpoint - The approval of the sodium bicarbonate injection by the National Medical Products Administration is expected to enhance market expansion and sales for the company, although it will not have a significant impact on current performance [1]. Company Summary - The full subsidiary of China National Pharmaceutical Group, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of sodium bicarbonate injection [1]. - The sodium bicarbonate injection is classified as an antacid and is indicated for the treatment of metabolic acidosis and the prevention of uric acid kidney stones [1]. - The company has invested approximately 2.7442 million in research and development for this product [1]. Industry Summary - The estimated sales for public medical institutions nationwide in 2024 for sodium bicarbonate injection are approximately 580 million [1]. - Other companies that have passed the consistency evaluation include Hefei Yuanfengshun Pharmaceutical Technology Co., Ltd. [1].